The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Open accessAbstract
Effective therapy for Alzheimer’s disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer’s disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer’s disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“These copolymers degrade by hydrolysis in the body to generate monomeric components and they are removed from body through different natural mechanisms [114].”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Cyclodextrins and their uses: a review
Del Valle, E. M. M. (2004) · Process Biochemistry · doi:10.1016/s0032-9592(03)00258-9 · Cited by 3,375
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Research works printed but not linked: 110
- 2007, Current Therapeutic Options for Alzheimer’s Disease, Curr. Genom., 8, 550, 10.2174/138920207783769549 · DOI
- Swanson, 2018, Treatment of early AD subjects with BAN2401, an anti-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline, Alzheimer’s Dement., 14, P1668, 10.1016/j.jalz.2018.07.009 · DOI
- Redzic, 2011, Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: Similarities and differences, Fluids Barriers CNS, 8, 3, 10.1186/2045-8118-8-3 · DOI · Paper page
- Pardridge, 2005, The Blood-Brain Barrier: Bottleneck in Brain Drug Development, NeuroRx, 2, 3, 10.1602/neurorx.2.1.3 · DOI · Paper page
- Sercombe, 2015, Advances and Challenges of Liposome Assisted Drug Delivery, Front. Pharmacol., 6, 286, 10.3389/fphar.2015.00286 · DOI · Paper page
- Tiwari, 2012, Drug delivery systems: An updated review, Int. J. Pharm. Investig., 2, 2, 10.4103/2230-973X.96920 · DOI · Paper page
- Goh, 2013, Changes in Brain Function Occur Years before the Onset of Cognitive Impairment, J. Neurosci., 33, 18008, 10.1523/JNEUROSCI.1402-13.2013 · DOI · Paper page
- Oh, 2014, Neural compensation in older people with brain amyloid-β deposition, Nat. Neurosci., 17, 1316, 10.1038/nn.3806 · DOI · Paper page
- Sun, 2015, β-Amyloid: The key peptide in the pathogenesis of Alzheimer’s disease, Front. Pharmacol., 6, 221, 10.3389/fphar.2015.00221 · DOI · Paper page
- Louise, 2000, Alzheimer’s amyloid fibrils: Structure and assembly, BBA—Mol. Basis Dis., 1502, 16, 10.1016/S0925-4439(00)00029-6 · DOI · Paper page
- Singh, 2016, Overview of Alzheimer’s Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds, Oxidative Med. Cell. Longev., 2016, 1, 10.1155/2016/7361613 · DOI · Paper page
- Wang, F., Zhou, X.-L., Yang, Q.-G., Xu, W.-H., Wang, F., Chen, Y.-P., and Chen, G.-H. (2011). A Peptide That Binds Specifically to the β-Amyloid of Alzheimer’s Disease: Selection and Assessment of Anti-β-Amyloid Neurotoxic Effects. PLoS ONE, 6. · DOI
- Reddy, 2008, Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease, Trends Mol. Med., 14, 45, 10.1016/j.molmed.2007.12.002 · DOI · Paper page
- Butterfield, 2013, Amyloid β-Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression, Antioxid. Redox Signal., 19, 823, 10.1089/ars.2012.5027 · DOI · Paper page
- Masahir, K., Isao, O., Shoko, Y., Midori, K., and Yutaka, S. (2011). Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer’s β-Amyloid Protein. Int. J. Alzheimer’s Dis., 2011. · DOI
- Demuro, 2010, Calcium signaling and amyloid toxicity in Alzheimer disease, J. Biol. Chem., 285, 12463, 10.1074/jbc.R109.080895 · DOI · Paper page
- Diniz, 2009, Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?, Dement. Neuropsychol., 3, 188, 10.1590/S1980-57642009DN30300003 · DOI
- Gong, 2008, Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease, Curr. Med. Chem., 15, 2321, 10.2174/092986708785909111 · DOI · Paper page
- Liu, 2013, Apolipoprotein E and Alzheimer disease: Risk, mechanisms, and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263 · DOI · Paper page
- Boucau, 2018, ABCA7 downregulation modifies cellular cholesterol homeostasis and decreases amyloid-β peptide efflux in an in vitro model of the blood-brain barrier, J. Alzheimer’s Dis., 64, 1195, 10.3233/JAD-170883 · DOI · Paper page
- Rodriguez, 2010, The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: The former opens to the portal blood and the latter to the cerebrospinal fluid, Peptides, 31, 757, 10.1016/j.peptides.2010.01.003 · DOI · Paper page
- Volterra, 2005, Astrocytes, from brain glue to communication elements: The revolution continues, Nat. Rev. Neurosci., 6, 626, 10.1038/nrn1722 · DOI · Paper page
- Peppiatt, 2006, Bidirectional control of CNS capillary diameter by pericytes, Nature, 443, 700, 10.1038/nature05193 · DOI · Paper page
- Chen, 2012, Modern methods for delivery of drugs across the blood-brain barrier, Adv. Drug Deliv. Rev., 64, 640, 10.1016/j.addr.2011.11.010 · DOI · Paper page
- Fischer, 1998, Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion, J. Membr. Biol., 165, 201, 10.1007/s002329900434 · DOI · Paper page
- Rishton, 2006, Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer’s disease, Curr. Opin. Drug Discov. Dev., 9, 303
- Kelder, 1999, Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs, Pharm. Res., 16, 1514, 10.1023/A:1015040217741 · DOI · Paper page
- Alam, 2010, Strategy for effective brain drug delivery, Eur. J. Pharm. Sci., 40, 385, 10.1016/j.ejps.2010.05.003 · DOI · Paper page
- Fong, 2015, Permeability of the Blood-Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds, J. Membr. Biol., 248, 651, 10.1007/s00232-015-9778-9 · DOI · Paper page
- Simpson, 2001, Glucose transporter asymmetries in the bovine blood-brain barrier, J. Biol. Chem., 276, 12725, 10.1074/jbc.M010897200 · DOI · Paper page
- Pardridge, 1992, Recent developments in peptide drug delivery to the brain, Pharmacol. Toxicol., 71, 3, 10.1111/j.1600-0773.1992.tb00512.x · DOI
- Bickel, 2001, Delivery of peptides and proteins through the blood-brain barrier, Adv. Drug Deliv. Rev., 46, 247, 10.1016/S0169-409X(00)00139-3 · DOI · Paper page
- Kumagai, 1987, Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport, J. Biol. Chem., 262, 15214, 10.1016/S0021-9258(18)48160-4 · DOI · Paper page
- Kokryakov, 1993, Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins, FEBS Lett., 327, 231, 10.1016/0014-5793(93)80175-T · DOI · Paper page
- Drin, 2002, Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors, AAPS Pharmsci., 4, 61, 10.1208/ps040426 · DOI
- Rousselle, 2001, Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: Saturation kinetics and specificity, J. Pharmacol. Exp. Ther., 296, 124
- Rousselle, 2002, Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy, J. Drug Target., 10, 309, 10.1080/10611860290031886 · DOI
- Brodin, 1997, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem., 272, 16010, 10.1074/jbc.272.25.16010 · DOI · Paper page
- Wender, 2000, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA, 97, 13003, 10.1073/pnas.97.24.13003 · DOI · Paper page
- Santra, 2005, Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots, Chem. Commun., 25, 3144, 10.1039/b503234b · DOI · Paper page
- Catania, 2016, Tackling amyloidogenesis in Alzheimer’s disease with A2V variants of Amyloid-β, Sci. Rep., 6, 20949, 10.1038/srep20949 · DOI
- Giunta, 2009, HIV-1 Tat contributes to Alzheimer’s disease-like pathology in PSAPP mice, Int. J. Clin. Exp. Pathol., 2, 433
- Hategan, 2017, HIV-Tat protein and amyloid β peptide form multifibrillar structures that cause neurotoxicity, Nat. Struct. Mol. Biol., 24, 379, 10.1038/nsmb.3379 · DOI
- Wu, 2015, Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer’s Rodent Models, Sci. Rep., 5, 15032, 10.1038/srep15032 · DOI
- Cheng, 2017, An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice, Embo Mol. Med., 9, 703, 10.15252/emmm.201606666 · DOI
- Hennink, 2011, In Vivo Methods to Study Uptake of Nanoparticles into the Brain, Pharm. Res., 28, 456, 10.1007/s11095-010-0291-7 · DOI
- Moos, 2000, Transferrin and transferrin receptor function in brain barrier systems, Cell. Mol. Neurobiol., 20, 77, 10.1023/A:1006948027674 · DOI · Paper page
- Kalaria, 1992, Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer’s disease, Brain Res., 585, 87, 10.1016/0006-8993(92)91193-I · DOI
- Zhang, 2001, Rapid transferrin efflux from brain to blood across the blood-brain barrier, J. Neurochem., 76, 1597, 10.1046/j.1471-4159.2001.00222.x · DOI · Paper page
- Gaillard, 2007, Drug targeting to the brain, Annu. Rev. Pharmacol. Toxicol., 47, 323, 10.1146/annurev.pharmtox.47.120505.105237 · DOI · Paper page
- Saito, 1995, Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex, Proc. Natl. Acad. Sci. USA, 92, 10227, 10.1073/pnas.92.22.10227 · DOI · Paper page
- Pardridge, 1998, Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm. Res., 15, 576, 10.1023/A:1011981927620 · DOI
- Boado, 1998, Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS, J. Pharm. Sci., 87, 1308, 10.1021/js9800836 · DOI
- Lee, 2000, Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse, J. Pharmacol. Exp. Ther., 292, 1048
- Pardridge, 1985, Human blood-brain barrier insulin receptor, J. Neurochem., 44, 1771, 10.1111/j.1471-4159.1985.tb07167.x · DOI · Paper page
- Shiiki, 2004, Brain insulin impairs amyloid-beta(1-40) clearance from the brain, J. Neurosci., 24, 9632, 10.1523/JNEUROSCI.2236-04.2004 · DOI
- Xie, 2002, Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor, J. Neurosci., 22, RC221, 10.1523/JNEUROSCI.22-10-j0001.2002 · DOI · Paper page
- Pardridge, 1995, Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate, Pharm. Res., 12, 807, 10.1023/A:1016244500596 · DOI · Paper page
- Coloma, 2000, Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor, Pharm. Res., 17, 266, 10.1023/A:1007592720793 · DOI · Paper page
- Hwang, 2005, Immunogenicity of engineered antibodies, Methods, 36, 3, 10.1016/j.ymeth.2005.01.001 · DOI · Paper page
- Boado, 2007, Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier, Biotechnol. Bioeng., 96, 381, 10.1002/bit.21120 · DOI · Paper page
- Boado, 2007, Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation, Bioconjug. Chem., 18, 447, 10.1021/bc060349x · DOI
- Boado, 2010, IgG-Single Chain Fv Fusion Protein Therapeutic for Alzheimer’s Disease: Expression in CHO Cells and Pharmacokinetics and Brain Delivery in the Rhesus Monkey, Biotechnol. Bioeng., 105, 627, 10.1002/bit.22576 · DOI
- Ohshima-Hosoyama, S., Simmons, H.A., Goecks, N., Joers, V., Swanson, C.R., Bondarenko, V., Velotta, R., Brunner, K., Wood, L.D., and Hruban, R.H. (2012). A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE, 7. · DOI
- Bu, 1994, Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons, J. Biol. Chem., 269, 18521, 10.1016/S0021-9258(17)32340-2 · DOI · Paper page
- Gaillard, 2005, Targeted delivery across the blood-brain barrier, Expert Opin. Drug Deliv., 2, 299, 10.1517/17425247.2.2.299 · DOI
- Frautschy, 2005, Low density lipoprotein receptor-related proteins (LRPs), Alzheimer’s and cognition, Curr. Drug Targets CNS Neurol. Disord., 4, 469, 10.2174/156800705774322102 · DOI · Paper page
- Hughes, 1998, Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation, Proc. Natl. Acad. Sci. USA, 95, 3275, 10.1073/pnas.95.6.3275 · DOI · Paper page
- Narita, 1997, Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein, J. Neurochem., 69, 1904, 10.1046/j.1471-4159.1997.69051904.x · DOI · Paper page
- Blacker, 1998, Alpha-2 macroglobulin is genetically associated with Alzheimer disease, Nat. Genet., 19, 357, 10.1038/1243 · DOI · Paper page
- Chen, 2010, Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery, Eur. J. Pharm. Sci., 40, 94, 10.1016/j.ejps.2010.03.007 · DOI
- Huang, 2007, Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain, J. Biomed. Sci., 14, 121, 10.1007/s11373-006-9121-7 · DOI
- Kawamata, 1993, Lactotransferrin immunocytochemistry in Alzheimer and normal human brain, Am. J. Pathol., 142, 1574
- Kennard, 1996, Serum levels of the iron binding protein p97 are elevated in Alzheimer’s disease, Nat. Med., 2, 1230, 10.1038/nm1196-1230 · DOI · Paper page
- Demeule, 2002, High transcytosis of melanotransferrin (P97) across the blood-brain barrier, J. Neurochem., 83, 924, 10.1046/j.1471-4159.2002.01201.x · DOI · Paper page
- Richardson, 2004, Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood–brain barrier, Int. Congr. Ser., 1277, 171
- Pan, 2004, Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier, J. Cell Sci., 117, 5071, 10.1242/jcs.01381 · DOI
- Choi, 2011, Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability, Proc. Natl. Acad. Sci. USA, 108, 9256, 10.1073/pnas.1018790108 · DOI · Paper page
- Raliya, 2017, Non-invasive aerosol delivery and transport of gold nanoparticles to the brain, Sci. Rep., 7, 44718, 10.1038/srep44718 · DOI
- Hanson, L.R., Fine, J.M., Svitak, A.L., and Faltesek, K.A. (2013). Intranasal Administration of CNS Therapeutics to Awake Mice. J. Vis. Exp., 4440. · DOI · Paper page
- Etame, 2012, Focused ultrasound disruption of the blood-brain barrier: A new frontier for therapeutic delivery in molecular neurooncology, Neurosurg. Focus, 32, E3, 10.3171/2011.10.FOCUS11252 · DOI
- Gosselet, 2013, Amyloid-β peptides, Alzheimer’s disease and the blood-brain barrier, Curr. Alzheimer Res., 10, 1015, 10.2174/15672050113106660174 · DOI · Paper page
- Suri, 2007, Nanotechnology-based drug delivery systems, J. Occup. Med. Toxicol., 2, 16, 10.1186/1745-6673-2-16 · DOI · Paper page
- Sathya, 2017, Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function, Artif. Cellsnanomed. Biotechnol., 25, 1
- Fornaguera, 2015, Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases, Nanoscale, 7, 12076, 10.1039/C5NR03474D · DOI
- Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., and Kumar, D.S. (2012). Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer’s Disease. PLoS ONE, 7. · DOI · Paper page
- Anand, 2010, Design of Curcumin Loaded PLGA Nanoparticles Formulation with Enhanced Cellular Uptake, and Increased Bioactivity in vitro and Superior Bioavailability in vivo, Biochem. Pharmacol., 79, 330, 10.1016/j.bcp.2009.09.003 · DOI · Paper page
- Huang, 2017, PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice, Oncotarget, 8, 81001, 10.18632/oncotarget.20944 · DOI · Paper page
- Ettcheto, 2017, New potential strategies for Alzheimer’s disease prevention: Pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9, Nanomedicine, 13, 1171, 10.1016/j.nano.2016.12.003 · DOI
- Carradori, 2018, Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model, Nanomedicine, 14, 609, 10.1016/j.nano.2017.12.006 · DOI
- Akbarzadeh, 2013, Liposome: Classification, preparation, and applications, Nanoscale Res. Lett., 8, 102, 10.1186/1556-276X-8-102 · DOI · Paper page
- Milla, 2012, PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery, Curr. Drug Metab., 13, 105, 10.2174/138920012798356934 · DOI · Paper page
- Mutlu, 2011, New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations, Drug Dev. Ind. Pharm., 37, 775, 10.3109/03639045.2010.541262 · DOI
- Zheng, 2015, Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease, Pharm. Res., 32, 3837, 10.1007/s11095-015-1744-9 · DOI · Paper page
- Chen, 2016, Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier, Nanomedicine, 12, 421, 10.1016/j.nano.2015.10.021 · DOI
- Kuo, 2014, Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin, Biomaterials, 35, 5954, 10.1016/j.biomaterials.2014.03.082 · DOI
- Kuo, 2017, Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin, Int. J. Nanomed., 12, 2857, 10.2147/IJN.S132472 · DOI
- Markoutsa, 2014, Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies, Pharm. Res., 31, 1275, 10.1007/s11095-013-1249-3 · DOI
- Mourtas, 2014, Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease, Eur. J. Med. Chem., 80, 175, 10.1016/j.ejmech.2014.04.050 · DOI · Paper page
- Shankar, 2016, A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: Formation mechanism and applications, Enzym. Microb. Technol., 95, 28, 10.1016/j.enzmictec.2016.10.015 · DOI · Paper page
- Yuna, 2016, How Do the Size, Charge and Shape of Nanoparticles Affect Amyloid β Aggregation on Brain Lipid Bilayer?, Sci. Rep., 6, 19548, 10.1038/srep19548 · DOI
- Rai, 2018, A nanoformulation for the preferential accumulation in adult neurogenic niches, J. Control Release, 284, 57, 10.1016/j.jconrel.2018.06.013 · DOI
- Nan, 2015, Gold-Nanoparticle-Based Multifunctional Amyloid-b Inhibitor against Alzheimer’s Disease, Chemistry, 21, 829, 10.1002/chem.201404562 · DOI · Paper page
- Coisne, C., Tilloy, S., Monflier, E., Wils, D., Fenart, L., and Gosselet, F. (2016). Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules, 21. · DOI
- Yao, 2012, Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease, J. Exp. Med., 209, 2501, 10.1084/jem.20121239 · DOI · Paper page
- Fenyvesi, 2014, Cyclodextrins, blood-brain barrier, and treatment of neurological diseases, Arch. Med. Res., 45, 711, 10.1016/j.arcmed.2014.11.020 · DOI
- Tilloy, 2006, Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier, Bioorg. Med. Chem. Lett., 16, 2154, 10.1016/j.bmcl.2006.01.049 · doi:10.1016/j.bmcl.2006.01.049
- Gil, 2012, β-cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier, Biomacromolecules, 13, 3533, 10.1021/bm3008633 · DOI
- Shawahna, 2013, Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: A special focus on transporters and metabolizing enzymes, Curr. Drug Metab., 14, 120, 10.2174/138920013804545232 · DOI
- Zhang, 2015, Drug-in-cyclodextrin-in-liposomes: A novel drug delivery system for flurbiprofen, Int. J. Pharm., 492, 40, 10.1016/j.ijpharm.2015.07.011 · DOI
Cited by
The Bioavailability of Drugs—The Current State of Knowledge
Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28248038 · Cited by 391
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Koo, J., Lim, C., & Oh, K. T. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439181 · Cited by 174
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Metadata
- Authors
- Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-17
- Volume
- 20
- Issue
- 2
- Pages
- 381
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2910423533
- Cited by
- 213
- References
- 34
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Hong Kong Baptist University (FRG2/16-17/073, and FRG2/15-16/078)
- Science and Technology Planning Project of Guangdong Province (2017A050506027)
- Science and Technology Program of Guangzhou (201807010053)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. https://app.cochat.ai/papers/10.3390/ijms20020381
- The paper
- Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019). Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20020381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.